HLA-typing, clinical, and immunological characterization of youth with type 2 diabetes mellitus phenotype from the German/Austrian DPV database
Article first published online: 30 APR 2013
© 2013 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
Volume 14, Issue 8, pages 562–574, December 2013
How to Cite
on behalf of the DPV Initiative and the German BMBF Competence Networks Diabetes Mellitus and Obesity. HLA-typing, clinical, and immunological characterization of youth with type 2 diabetes mellitus phenotype from the German/Austrian DPV database., , , , , , , , , , , , , ,
- Issue published online: 26 NOV 2013
- Article first published online: 30 APR 2013
- Manuscript Accepted: 26 MAR 2013
- Manuscript Revised: 30 JAN 2013
- Manuscript Received: 24 SEP 2012
- German Federal Ministry of Health
- BMBF Competence Network Diabetes. Grant Number: 01GI1106
- Competence Network Obesity. Grant Number: 01GI1130
- Novo Nordisk Germany
- Dr. Bürger-Büsing Foundation
- Centre of Excellence ‘metabolic diseases’ of the Federal State of Baden-Württemberg
- type 2 diabetes;
- β-cell autoimmunity
To characterize the clinical and immunological features of HLA-typed youth with pediatric onset of type 2 diabetes mellitus (T2DM).
One hundred and seven patients with clinically diagnosed T2DM (aged ≤20 yr at diagnosis) were examined. DNA and serum, obtained after a median diabetes duration of 2.2 (Q1–Q3: 0.8–4.6) yr, were used for centralized HLA-typing and autoantibody (GADA, IA-2A, ZnT8A) measurements.
64.6% of patients were female and median age at diagnosis was 13.8 (Q1–Q3: 11.6–15.4) yr. Patients were obese [median body mass index-standard deviation score (BMI-SDS): 2.6 (2.0–3.1)], 88.0% had a family history of diabetes and 40.2% a migration background. Islet autoantibodies were detected in 16 (15.0%), among which 7 (6.5%) had multiple islet autoantibodies. Autoantibody positive patients had poorer metabolic control than autoantibody negative patients [glycosylated hemoglobin A1c (HbA1c): 8.1 (6.9–10.1) % vs. 6.6 (5.9–8.0) %; p = 0.033], while patients with HLA-DR genetic risk had higher BMI-SDS than those with HLA-DRXX [2.6 (2.4–3.7) vs. 2.4 (1.7–2.9); p = 0.007]. Metabolic syndrome (61.7%), microalbuminuria (13.4%), and retinopathy (3.9%) were diagnosed. Therapies used were lifestyle only (35.5%), oral anti-diabetics (OAD) only (43.3 %), insulin + OAD (15.9%) and insulin only (5.6%). Patients with β-cell autoimmunity or HLA-DR genetic risk more frequently used insulin than confirmed T2DM patients (50.0 vs. 22.0%; p = 0.037) and less often had diabetic relatives (61.1 vs. 86.0%; p = 0.030).
T2DM was confirmed in about 90% of patients while about 10% with β-cell autoimmunity or HLA-DR genetic risk likely had either T1.5DM or ‘double diabetes’ or an unknown diabetes type.